- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00720356
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
A Phase II Study of Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bevacizumab together with erlotinib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with erlotinib works after radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
OBJECTIVES:
Primary
- To determine the overall survival of patients with newly diagnosed glioblastoma multiforme (GBM) with unmethylated MGMT promoter treated with bevacizumab and erlotinib hydrochloride after radiotherapy and temozolomide.
Secondary
- To determine the 12- and 24-month progression-free survival (PFS) of patients with newly diagnosed GBM with unmethylated MGMT promoter treated with this regimen.
- To assess radiographic response rates.
- To perform correlative tissue assays.
- To collect safety data on the combination of bevacizumab and erlotinib hydrochloride in patients with newly diagnosed GBM with unmethylated MGMT promoter treated with bevacizumab and erlotinib hydrochloride after radiotherapy and temozolomide.
OUTLINE: This is a multicenter study.
Patients undergo radiotherapy (either intensity-modulated radiation therapy or 3-D conformal radiotherapy) once daily 5 days a week and receive oral temozolomide concurrently with radiotherapy once daily for 6 weeks (as planned). Patients whose tumor has a methylated MGMT promoter are removed from study.
Approximately 4 weeks after completion of radiotherapy and temozolomide, patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment with bevacizumab and erlotinib hydrochloride repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at approximately 30 days and then every 3 months thereafter.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
California
-
Los Angeles, California, Stany Zjednoczone, 90048
- Cedars-Sinai Medical Center
-
-
Florida
-
Orlando, Florida, Stany Zjednoczone, 32806-2134
- M.D. Anderson Cancer Center at Orlando
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60611-3013
- Northwestern University, Northwestern Medical Faculty Foundation
-
Evanston, Illinois, Stany Zjednoczone, 60201-1781
- Evanston Hospital
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone, 75246
- Neuro-Oncology Associates at Baylor University Medical Center, Dallas
-
Houston, Texas, Stany Zjednoczone, 77030-4009
- M.D. Anderson Cancer Center at University of Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- The Methodist Hospital Neurological Institute
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 19024
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
DISEASE CHARACTERISTICS:
- Histologically confirmed newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma
- Undergoing or plan to undergo treatment with radiotherapy and concurrent temozolomide for 6 weeks
Unmethylated MGMT promoter status must be determined before completing radiotherapy
- Tumor must be MGMT negative to receive bevacizumab and erlotinib hydrochloride
Patients who are post biopsy or tumor resection allowed provided a post-operative MRI is done no more than 96 hours after surgery (in order for an accurate assessment to be done post radiotherapy):
- Evaluable or measurable disease after resection of recurrent tumor is not mandated for eligibility
Patients who started radiotherapy and temozolomide prior to study entry are eligible as long as the gene methylation status is determined before starting bevacizumab and erlotinib hydrochloride
- Radiotherapy plans need to be verified to confirm the treatment plan meets the study requirement based on the PI assessment
- No progressive disease based on MRI or CT scan per the investigators assessment
PATIENT CHARACTERISTICS:
- Karnofsky performance status 70-100%
- Life expectancy > 12 weeks
- WBC > 3,000/μL
- ANC > 1,500/mm³
- Platelet count > 100,000/mm³
- Hemoglobin > 10 g/dL
- SGOT/SGPT < 3 times upper limit of normal (ULN)
- Bilirubin < 3 times ULN
- Creatinine < 1.5 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
- No significant medical illness that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to tolerate this therapy, or any disease that will obscure toxicity or dangerously alter drug metabolism
No proteinuria at screening, as demonstrated by either of the following:
- Urine protein:creatinine (UPC) ratio < 1.0
- Urine dipstick for proteinuria < 2+ OR ≤ 1g protein by 24-hour urine collection
- No inadequately controlled hypertension (defined as systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 100 mm Hg) on antihypertensive medications
- No history of hypertensive crisis or hypertensive encephalopathy
- No New York Heart Association class II-IV congestive heart failure
- No history of myocardial infarction or unstable angina within 6 months prior to study enrollment
- No history of stroke or transient ischemic attack within 6 months of study enrollment
- No symptomatic peripheral vascular disease
- No significant vascular disease (i.e., aortic aneurysm or aortic dissection)
- No evidence of bleeding diathesis or coagulopathy
- No significant traumatic injury within 28 days prior to study enrollment
- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
- No serious, nonhealing wound, ulcer, or bone fracture
No known HIV positivity
- HIV testing is not required for study participation
- No history of any other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years
PRIOR CONCURRENT THERAPY:
- No chemotherapy is allowed prior to starting radiotherapy and temozolomide, including polifeprosan 20 with carmustine implant (Gliadel wafers)
- No major surgical procedure or open biopsy within 28 days prior to study enrollment or the anticipation of need for major surgical procedure during the course of the study
- No core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
Concurrent nonenzyme-inducing anticonvulsants allowed
- More than 2 weeks (before starting erlotinib hydrochloride and bevacizumab) since prior and no concurrent enzyme-inducing anticonvulsant
- No other concurrent experimental agents
- Not concurrently participating in other clinical trials
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Treatment
erlotinib and bevacizumab
|
10mg/kg administered intravenously every 2 weeks
Inne nazwy:
150 mg/daily orally
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Overall Survival
Ramy czasowe: From start of treatment, during treatment and every 3 months following the end of treatment until death. Median follow up at time of OS data was 33 months.
|
Overall survival (OS) will be measured from the start of treatment until death from any cause.
At data cut off patients remaining alive will be censored at the last known date of contact.
|
From start of treatment, during treatment and every 3 months following the end of treatment until death. Median follow up at time of OS data was 33 months.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Progression-free Survival at 12 Months
Ramy czasowe: At 12 months from start of treatment
|
Progression free survival (PFS) will be assessed by CT or MRI scan using McDonald criteria.
Progressive disease (PD) is defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).
Stable or increased dose of steroids.
PFS will be measured from the start of treatment until first documentation of PD or death.
|
At 12 months from start of treatment
|
Response Rate (RR)
Ramy czasowe: From the start of treatment, every 2 cycles (1 cycle = 28 days) during treatment until progressive disease
|
Response Rate (RR) will be defined as the best response seen during treatment measured by CT/MRI scan every 8 weeks during treatment using McDonald Criteria. CR=Complete disappearance of all measurable and evaluable disease. No new lesions. No evidence of non-evaluable disease. Patients off steroids. PR=Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions. Stable/decreased dose of steroids. Stable/No Response=Does not qualify for CR, PR, or progression. The designation of Stable/No Response requires a minimum of 8 weeks duration. Stable/decreased dose of steroids. Progressive disease = 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease), worsening of evaluable disease, new lesions/site, failure to return for evaluation due to death or deteriorating condition. |
From the start of treatment, every 2 cycles (1 cycle = 28 days) during treatment until progressive disease
|
Safety of the Combination of Erlotinib and Bevacizumab in This Patient Population
Ramy czasowe: From the start of treatment, at the beginning of every cycle (1 cycle = 28 days) during treatment until 30 days after completion of treatment for up to 49 cycles.
|
Toxicity data for combination treatment of erlotinib and bevacizumab will be collected on day 1 of every cycle (1 cycle = 28 days) during treatment according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v3.0). In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE |
From the start of treatment, at the beginning of every cycle (1 cycle = 28 days) during treatment until 30 days after completion of treatment for up to 49 cycles.
|
Progression Free Survival at 18 Months
Ramy czasowe: At 18 months from start of treatment
|
Progression free survival (PFS) will be assessed by CT or MRI scan using McDonald criteria.
Progressive disease (PD) is defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).
Stable or increased dose of steroids.
PFS will be measured from the start of treatment until first documentation of PD or death.
|
At 18 months from start of treatment
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Changes in Tumor Blood Flow Based on MR Perfusion
Ramy czasowe: Prior to study treatment (after surgery, but before radiation), just before study treatment (within 14 days prior to first treatment) and then every 2 cycles during study treatment, where 1 cycle equals 28 days for a maximum of 49 cycles.
|
Data from consenting patients will be used to assess of changes in tumor blood flow based on MR perfusion using MRI scans.
Two scans will be completed prior to treatment on study; the first after surgery buta before radiation, the second within 14 days before starting combination treatment or erlotinib and bevacizumab.
Then scans will be completed every 2 cycles during treatment, where one cycle equals 28 days.
|
Prior to study treatment (after surgery, but before radiation), just before study treatment (within 14 days prior to first treatment) and then every 2 cycles during study treatment, where 1 cycle equals 28 days for a maximum of 49 cycles.
|
Gene Methylation Studies (Optional)
Ramy czasowe: At baseline and then plasma only will be collected every odd cycle (1 cycle = 28 days) during treatment for a maximum of 49 cycles.
|
Tissue and plasma collected from consenting patients in the study will be used to correlate tumor tissue with imaging and outcomes.
Tissue will be collected before treatment on study begins and plasma will be collected the first day of treatment (before treatment) and every odd cycle after that, whilst on study treatment.
Tissue and plasma analysis will be correlated with patients imaging results and response to to treatment
|
At baseline and then plasma only will be collected every odd cycle (1 cycle = 28 days) during treatment for a maximum of 49 cycles.
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby Układu Nerwowego
- Nowotwory według typu histologicznego
- Nowotwory
- Nowotwory według lokalizacji
- Nowotwory gruczołowe i nabłonkowe
- Gwiaździak
- Glejak
- Nowotwory neuroepitelialne
- Nowotwory neuroektodermalne
- Nowotwory, komórki rozrodcze i embrionalne
- Nowotwory, tkanka nerwowa
- Glejaka wielopostaciowego
- Nowotwory Układu Nerwowego
- Nowotwory ośrodkowego układu nerwowego
- Glejak
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Inhibitory enzymów
- Środki przeciwnowotworowe
- Środki przeciwnowotworowe, immunologiczne
- Inhibitory angiogenezy
- Środki modulujące angiogenezę
- Substancje wzrostowe
- Inhibitory wzrostu
- Inhibitory kinazy białkowej
- Chlorowodorek erlotynibu
- Bewacyzumab
Inne numery identyfikacyjne badania
- NU 07C3 (Inny identyfikator: Northwestern University)
- BTTC08-01 (Inny identyfikator: U.T. M.D. Anderson Cancer Center)
- STU00002792 (Inny identyfikator: Northwestern University IRB)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na bevacizumab
-
Dana-Farber Cancer InstituteBristol-Myers Squibb; Genentech, Inc.ZakończonyCzerniakStany Zjednoczone
-
National Cancer Institute (NCI)NRG OncologyZakończonyGlejaka wielopostaciowego | Glejak | Nawracający glejak wielopostaciowy | Skąpodrzewiak | Glejak olbrzymiokomórkowy | Nawracający nowotwór mózguStany Zjednoczone, Kanada
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RekrutacyjnyNawracający rak jajowodu | Nawracający rak jajnika | Nawracający pierwotny rak otrzewnej | Gruczolakorak endometrioidalny jajnika | Rak jasnokomórkowy jajnika | Gruczolakorak jajowodu | Rak surowiczy jajowodu | Gruczolakorak surowiczy jajnika | Rak jajowodu | Rak jajnika | Pierwotny gruczolakorak otrzewnejStany Zjednoczone
-
M.D. Anderson Cancer CenterRekrutacyjnyRak wątrobowokomórkowy w stadium IB AJCC v8 | Rak wątrobowokomórkowy II stopnia AJCC v8 | Resekcyjny rak wątrobowokomórkowy | Rak wątrobowokomórkowy stopnia I AJCC v8 | Rak wątrobowokomórkowy w stadium IA AJCC v8Stany Zjednoczone
-
National Cancer Institute (NCI)Aktywny, nie rekrutującyNawracający rak jajowodu | Nawracający rak jajnika | Nawracający pierwotny rak otrzewnej | Cystadenocarcinoma jasnokomórkowego jajnika | Gruczolakorak endometrioidalny jajnika | Serous Cystadenocarcinoma jajnika | Gruczolakorak jasnokomórkowy endometrium | Gruczolakorak surowiczy endometrium | Nawracający... i inne warunkiStany Zjednoczone
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRekrutacyjnyNawracający rak jajowodu | Nawracający rak jajnika | Nawracający pierwotny rak otrzewnej | Nawracający gruczolakorak surowiczy endometrium | Rak jasnokomórkowy jajnika | Nawrotowy rak jajnika oporny na platynę | Rak jajnika wrażliwy na platynę | Nawracający gruczolakorak endometrioidalny jajowodu | Nawracający... i inne warunkiStany Zjednoczone
-
M.D. Anderson Cancer CenterAktywny, nie rekrutującyNiedrobnokomórkowy rak płuc z przerzutami | Rak płuc w stadium IVA AJCC v8 | Rak płuc w stadium IVB AJCC v8 | Rak płuc w stadium IV AJCC v8 | Rak płuc w stadium IIIC AJCC v8 | Nawracający niedrobnokomórkowy rak płucStany Zjednoczone
-
National Cancer Institute (NCI)ZakończonyGruczolakorak szyjki macicy | Rak gruczolakowaty szyjki macicy | Rak płaskonabłonkowy szyjki macicy, gdzie indziej niesklasyfikowany | Rak szyjki macicy w stadium IVA AJCC v6 i v7 | Nawracający rak szyjki macicy | Rak szyjki macicy stopnia IV AJCC v6 i v7 | Rak szyjki macicy w stadium IVB AJCC v6 i v7Stany Zjednoczone
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsZakończonyNawracający rak jajowodu | Nawracający rak jajnika | Nawracający pierwotny rak otrzewnej | Platynooporny rak jajowodu | Platynooporny pierwotny rak otrzewnej | Platynooporny rak jajnika | Oporny rak jajnika | Oporny na leczenie rak jajowodu | Oporny na leczenie pierwotny rak otrzewnejStany Zjednoczone
-
Mayo ClinicNational Cancer Institute (NCI)Aktywny, nie rekrutującyZłośliwy nowotwór lity | Gruczolakorak endometrioidalny jajnika | Niezróżnicowany rak jajnika | Gruczolakorak szyjki macicy | Rak gruczolakowaty szyjki macicy | Nowotwór złośliwy otrzewnej | Gruczolakorak jasnokomórkowy endometrium | Endometrialny gruczolakorak endometrioidalny | Mieszany gruczolakokomórkowy... i inne warunkiStany Zjednoczone